<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265950</url>
  </required_header>
  <id_info>
    <org_study_id>RG1007065</org_study_id>
    <secondary_id>U54CA242977</secondary_id>
    <secondary_id>NCI-2020-01098</secondary_id>
    <secondary_id>10521</secondary_id>
    <nct_id>NCT04265950</nct_id>
  </id_info>
  <brief_title>Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial</brief_title>
  <acronym>OPTIMO</acronym>
  <official_title>Multicenter, Randomized, Open-Label Trial in Children and Adolescents to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociacion Civil Via Libre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV trial compares 3 different dosing schedules to find the optimal number of doses&#xD;
      for HPV vaccination in children and adolescents living with HIV. Comparing 3 different dosing&#xD;
      schedules may help researchers determine whether a single dose of HPV vaccine could be&#xD;
      effective in preventing HPV in children and adolescents living with HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Participants living with HIV are randomized to one of three arms. HIV-negative&#xD;
      participants are assigned to a fourth arm.&#xD;
&#xD;
      ARM 1: Participants living with HIV receive recombinant human papillomavirus nonavalent&#xD;
      vaccine intramuscularly (IM) at enrollment, and at 2 and 6 months. Participants also receive&#xD;
      recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.&#xD;
&#xD;
      ARM 2: Participants living with HIV receive recombinant human papillomavirus nonavalent&#xD;
      vaccine IM at enrollment and at 6 months. Participants also receive recombinant human&#xD;
      papillomavirus nonavalent vaccine booster dose IM at 30 months.&#xD;
&#xD;
      ARM 3: Participants living with HIV receive recombinant human papillomavirus nonavalent&#xD;
      vaccine IM at enrollment. Participants also receive recombinant human papillomavirus&#xD;
      nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus&#xD;
      nonavalent vaccine completion dose IM at 30 months.&#xD;
&#xD;
      ARM 4: Participants without HIV receive recombinant human papillomavirus nonavalent vaccine&#xD;
      IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent&#xD;
      vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine&#xD;
      completion dose IM at 30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Human papillomavirus type 16 (HPV16) neutralizing antibody geometric mean titers (GMTs) (Arm 1 versus [vs.] Arm 2)</measure>
    <time_frame>At 24 months after the last dose of each vaccine regimen</time_frame>
    <description>Pseudovirion (PsV)-based neutralization assays will be used to establish HPV 16 neutralizing antibody GMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human papillomavirus type 18 (HPV18) neutralizing antibody GMTs (Arm 1 vs. Arm 2)</measure>
    <time_frame>At 24 months after the last dose of each vaccine regimen</time_frame>
    <description>Pseudovirion (PsV)-based neutralization assays will be used to establish HPV 18 neutralizing antibody GMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HPV16 and HPV18 binding antibody median fluorescence intensity-MFI (slope) (Arm 1 vs. Arm 2)</measure>
    <time_frame>Between 1 month after the last dose and 18 months after the last dose, and between 18 months and 24 months after the last dose of each vaccine regimen</time_frame>
    <description>The Luminex immunoassay-based assay will be used to measure HPV 16 and HPV 18 binding antibody MFI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV16 and HPV18 neutralizing antibody GMTs (Arm 2 vs. Arm 3)</measure>
    <time_frame>At 24 months after the last vaccine dose</time_frame>
    <description>Pseudovirion (PsV)-based neutralization assays will be used to establish HPV 16 and HPV 18 neutralizing antibody GMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HPV16 and HPV18 binding antibody MFI (slope) (Arm 2 vs. Arm 3)</measure>
    <time_frame>Between 1 month and 18 months after the last vaccine dose, and between 18 months and 24 months after the last vaccine dose</time_frame>
    <description>The Luminex immunoassay-based assay will be used to measure HPV 16 and HPV 18 binding antibody MFI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding antibody MFI to all 9 vaccine HPV types (Arm 2 vs. Arm 3)</measure>
    <time_frame>At month 7 in Arm 2 and month 25 in Arm 3</time_frame>
    <description>Compare the response to a 0, 6- months two-dose schedule vs. a 0, 24-months two-dose schedule in children living with HIV (CLWH). The Luminex immunoassay-based assay will be used to measure HPV 16 and HPV 18 binding antibody MFI, as well as the binding antibody MFI for other HPV types.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV16 and HPV18 neutralizing antibody GMTs (Arm 3 vs. Arm 4)</measure>
    <time_frame>At 24 months after the first (single) vaccine dose</time_frame>
    <description>Pseudovirion (PsV)-based neutralization assays will be used to establish HPV 16 and HPV 18 neutralizing antibody GMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HPV16 and HPV18 binding antibody MFI (slope) (Arm 3 vs. Arm 4)</measure>
    <time_frame>Between 1 month and 18 months after the single vaccine dose, and between 18 months and 24 months after the first (single) vaccine dose</time_frame>
    <description>The Luminex immunoassay-based assay will be used to measure HPV 16 and HPV 18 binding antibody MFI.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1 (3 doses of 9vHPV vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment, and at 2 and 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (2 doses of 9vHPV vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment and at 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (1 dose of 9vHPV vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (1 dose of 9vHPV vaccine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants without HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment . Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Human Papillomavirus Nonavalent Vaccine</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm 1 (3 doses of 9vHPV vaccine)</arm_group_label>
    <arm_group_label>Arm 2 (2 doses of 9vHPV vaccine)</arm_group_label>
    <arm_group_label>Arm 3 (1 dose of 9vHPV vaccine)</arm_group_label>
    <arm_group_label>Arm 4 (1 dose of 9vHPV vaccine)</arm_group_label>
    <other_name>Gardasil 9</other_name>
    <other_name>Nonavalent HPV VLP Vaccine</other_name>
    <other_name>Recombinant HPV Nonavalent Vaccine</other_name>
    <other_name>Recombinant Human Papillomavirus 9-valent Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ARMS 1-3: Children must be living with HIV. HIV infection must be confirmed by local&#xD;
             algorithm (positive nucleic acid amplification test [NAAT] test before 18 months of&#xD;
             age and/or positive serologic test thereafter)&#xD;
&#xD;
          -  ARM 4: Children must be healthy (e.g., without autoimmune disease or cancer) and not&#xD;
             infected with HIV&#xD;
&#xD;
          -  ARMS 1-3: Children must be on a consistent, clinically appropriate combination&#xD;
             antiretroviral therapy (ART) regimen for &gt; 6 months prior to study enrollment&#xD;
&#xD;
          -  Children must be 9-13 years-old (at or after 9th birthday, prior to 14th birthday) at&#xD;
             enrollment. This will allow vaccination of participants within the recommended age&#xD;
             range for receipt of HPV vaccination in Peru and Brazil. Only children ages 9-11 (at&#xD;
             or after 9th birthday, prior to 12th birthday) will be enrolled into arms 3 and 4&#xD;
&#xD;
          -  ARMS 1-3: CD4% &gt; 15% or CD4 counts &gt; 200 cells/mm^3 (within 6 months prior to study&#xD;
             entry)&#xD;
&#xD;
          -  ARMS 1-3: Viral load (VL) &lt; 400 copies/mL (within 6 months prior to study entry)&#xD;
&#xD;
          -  All female participants must not be pregnant (all females will receive pregnancy tests&#xD;
             at all vaccine visits prior to receipt of study vaccine). The effects of Gardasil 9 on&#xD;
             the developing human fetus at the recommended therapeutic dose are unknown. If&#xD;
             pregnancy is confirmed during the screening process, enrollment will not occur. If&#xD;
             pregnancy occurs after the first vaccine dose, additional vaccine doses will not be&#xD;
             administered, but the child will remain in study follow-up&#xD;
&#xD;
          -  It is anticipated that all children will enter the study prior to sexual debut,&#xD;
             although this will not be investigated clinically. Potential participants who report&#xD;
             sexual activity will not be enrolled&#xD;
&#xD;
          -  Children in all arms must have the ability to understand and the willingness to assent&#xD;
             to the study. Parents or guardians must be able to understand and willing to sign a&#xD;
             written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children who have a serious illness requiring treatment with systemic medications&#xD;
             other than ART (excluding short course oral steroids or inhaled steroid treatment for&#xD;
             asthma), are currently under immunomodulatory therapy, received immunosuppressive&#xD;
             therapy (&gt; 10 mg/day of prednisone or equivalent for &gt; 1 week) in the 6 months prior&#xD;
             to enrollment date&#xD;
&#xD;
          -  Children who received any vaccine within 3 weeks prior to enrollment date (these&#xD;
             children will be encouraged to enroll after 3 weeks have passed)&#xD;
&#xD;
          -  Children who received blood-derived products within 6 months prior to enrollment or&#xD;
             planned use during the study period&#xD;
&#xD;
          -  Children who weigh less than 18 kilograms&#xD;
&#xD;
          -  Children with cancer being treated with chemotherapy or radiation&#xD;
&#xD;
          -  Potential participants receiving any other investigational agents may be excluded in&#xD;
             the opinion of the supervising physician&#xD;
&#xD;
          -  Children in all arms with contraindications to vaccination, including pregnancy or&#xD;
             breastfeeding&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Children who are enrolled and later found to be seropositive for HPV at study entry&#xD;
             (by Luminex assay performed by the Central Laboratory Core in Seattle) will be&#xD;
             discontinued from the study&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to HPV vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Duerr, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Duerr, MD, PhD</last_name>
    <phone>206-667-7938</phone>
    <email>aduerr@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ) STD and AIDS Clinical Research Laboratory</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Beatriz Grinsztejn</last_name>
      <phone>+55-21-2270-7064</phone>
      <email>gbeatriz@ipec.fiocruz.br</email>
    </contact>
    <contact_backup>
      <phone>+55-21-3865-9128</phone>
    </contact_backup>
    <investigator>
      <last_name>Beatriz Grinsztejn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asociaci√≥n Civil Via Libre</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Robinson Cabello</last_name>
      <phone>(+511) 203-9900</phone>
      <email>rcabello@vialibre.org.pe</email>
    </contact>
    <investigator>
      <last_name>Robinson Cabello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Peru</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccination</keyword>
  <keyword>HIV infected children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

